The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL

International Urology and Nephrology

Volumn 46, Issue 4, 2014, Pages 711-717

  Ng, C F ^a   Chiu, Peter K F ^a   Lam, N Y ^a   Lam, H C ^a   Lee, Kim W M ^a   Hou, Simon S M ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Biomarkers; Prostate cancer; Prostate specific antigen; PSA density; PSA isoform; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ISOPROTEIN; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASIAN; CANCER DIAGNOSIS; CONTROLLED STUDY; DENSITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX; PROSTATE VOLUME; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SERUM; TRANSRECTAL ULTRASONOGRAPHY; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CANCER GRADING; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; MIDDLE AGED; ORGAN SIZE; PATHOLOGY; PREDICTIVE VALUE; PROSTATE; PROSTATE TUMOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; ORGAN SIZE; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RETROSPECTIVE STUDIES; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84897509174     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-013-0582-0     Document Type: Article

References (19)

1. Sim HG, Cheng CW (2005) Changing demography of prostate cancer in Asia. Eur J Cancer 41:834-845
2. Loeb S, Catalona WJ (2010) Prostate-specific antigen screening: pro. Curr Opin Urol 20:185-188
3. Zaytoun OM, Anil T, Moussa AS, Jianbo L, Fareed K, Jones JS (2011) Morbidity of prostate biopsy after simplified versus complex preparation protocols: assessment of risk factors. Urology 77:910-914
4. Wagenlehner FM, van Oostrum E, Tenke P, Tandogdu Z, Cek M, Grabe M, Wullt B, Pickard R, Naber KG, Pilatz A, Weidner W, Bjerklund-Johansen TE, On behalf of the GPIU investigators (2013) Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol 63:521-527
5. Tosoian J, Loeb S (2010) PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer. Sci World J 10:1919-1931
6. Jansen FH, van Schaik RH, Kurstjens J, Horninger W, Klocker H, Bektic J, Wildhagen MF, Roobol MJ, Bangma CH, Bartsch G (2010) Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 57:921-927
7. Guazzoni G, Nava L, Lazzeri M, Scattoni V, Lughezzani G, Maccagnano C, Dorigatti F, Ceriotti F, Pontillo M, Bini V, Freschi M, Montorsi F, Rigatti P (2011) Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10.0 ng/ml: results of a prospective study in a clinical setting. Eur Urol 60:214-222
8. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA (2011) A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 185:1650-1655
9. Filella X, Giménez N (2013) Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-Analysis. Clin Chem Lab Med 51:729-739
10. Chun FK, Epstein JI, Ficarra V, Freedland SJ, Montironi R, Montorsi F, Shariat SF, Schröder FH, Scattoni V (2010) Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature. Eur Urol 58:851-864
11. Bjurlin MA, Carter HB, Schellhammer P, Cookson MS, Gomella LG, Troyer D, Wheeler TM, Schlossberg S, Penson DF, Taneja SS (2013) Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol 189:2039-2046
12. Rodrigues G, Warde P, Pickles T, Crook J, Brundage M, Souhami L, Lukka H, Genitourinary Radiation Oncologists of Canada (2012) Pre-treatment risk stratification of prostate cancer patients: a critical review. Can Urol Assoc J 6:121-127
13. Ito K, Miyakubo M, Sekine Y, Koike H, Matsui H, Shibata Y, Suzuki K (2013) Diagnostic significance of [-2]pro-PSA and prostate dimension-Adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range. World J Urol 31:305-311
14. Stephan C, Vincendeau S, Houlgatte A, Cammann H, Jung K, Semjonow A (2013) Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem 59:306-314
15. Nichol MB, Wu J, Huang J, Denham D, Frencher SK, Jacobsen SJ (2011) Cost-effectiveness of Prostate Health Index for prostate cancer detection. BJU Int 110:353-362
16. Sokoll LJ, Ellis W, Lange P, Noteboom J, Elliott DJ, Deras IL, Blase A, Koo S, Sarno M, Rittenhouse H, Groskopf J, Vessella RL (2008) A multicenter evaluation of the PCA3 molecular urine test: pre-Analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta 389:1-6
17. Roobol MJ, Schröder FH, van Leeuwen P, Hessels D, van den Bergh RC, Wolters T, van Leeuwen PJ (2010) Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 58:893-899
18. Semjonow A, Köpke T, Eltze E, Pepping-Schefers B, Burgel H, Darte C (2010) Pre-Analytical in vitro stability of [-2]proPSA in blood and serum. Clin Chem 43:926-928
19. ® prostate-specific antigen assays. Clin Chem Lab Med 48:285-288